About Viking therapeutics, inc.
Viking Therapeutics, Inc. is a biopharmaceutical company that specializes in developing novel therapeutics for metabolic and endocrine disorders. The company's mission is to improve the lives of patients suffering from these conditions by providing innovative treatments that address unmet medical needs.
With a team of experienced scientists and researchers, Viking Therapeutics is at the forefront of developing cutting-edge therapies for metabolic and endocrine disorders such as non-alcoholic steatohepatitis (NASH), type 2 diabetes, and other related conditions. The company's focus on these areas stems from the growing prevalence of these diseases worldwide, which has led to an urgent need for effective treatments.
One of Viking Therapeutics' most promising drug candidates is VK2809, a thyroid hormone receptor beta agonist that has shown significant potential in treating NASH. In clinical trials, VK2809 has demonstrated its ability to reduce liver fat content and improve liver function in patients with NASH. This drug candidate also holds promise for treating other metabolic disorders such as dyslipidemia and hypercholesterolemia.
Another key area of focus for Viking Therapeutics is type 2 diabetes. The company's lead drug candidate in this area is VK0612, a glucagon receptor antagonist that has shown promising results in preclinical studies. By blocking the action of glucagon, VK0612 may help regulate blood glucose levels in patients with type 2 diabetes.
In addition to its pipeline of drug candidates, Viking Therapeutics also collaborates with leading academic institutions and research organizations to advance scientific understanding of metabolic and endocrine disorders. Through these partnerships, the company aims to identify new targets for drug development and accelerate the discovery process.
Overall, Viking Therapeutics' commitment to innovation and patient-centered care makes it an exciting player in the biopharmaceutical industry. With its strong pipeline of novel therapeutics targeting metabolic and endocrine disorders like NASH and type 2 diabetes, this company holds great promise for improving patient outcomes around the world.